Among them, E7107 has been shown to enhance antitumor response when combined with the proteasome inhibitor, bortezomib, in triple-negative breast cancer, thus highlighting the possible usage of mutant SF3B1 inhibitors in combination therapies. Here, SF3B1 is linked to triple-negative breast carcinoma.